Erdosteine Market - By Application (Bronchitis, Chronic Obstructive Pulmonary Disease, Nasopharyngitis), By End-Use (Pharmaceutical, Contract Manufacturing Companies, Research Institute) & Forecast, 2021-2027

Erdosteine Market Size

Global Erdosteine Market size surpassed USD 105 million in 2020 and is likely to grow at a CAGR of 8.3% by 2027. The product is a molecule with free radical scavenging and mucolytic properties. Significant rise in the incidence of bronchitis primarily in the U.S., UK and Spain represents ample growth opportunities for erdosteine owing to its high effectiveness in reducing the symptoms of acute flareups in chronic bronchitis.
 

Growing focus on disease prevention rather than treatment and government prioritization towards healthcare funding has resulted in growing adoption of erdosteine by research institutes. The growing prevalence of adults with chronic diseases such as diabetes, obesity and heart disease has increased the requirement for therapeutic treatments which should drive the pharmaceutical research sector and augment the erdosteine market share.
 

Erdosteine Market Analysis

Chronic obstructive pulmonary disease (COPD) application surpassed USD 54.5 million in 2020 and should witness over 8% gains in the forecast period. A substantial rise in aging populations in many countries such as Japan, Italy and Greece along with growing prevalence of smoking is likely to boost the incidence of COPD in the forecast timeframe. The serious, life-threatening nature of COPD apart from its tendency to progress with time should drive the erdosteine market share growth.
 

The growing adoption of tobacco-smoking in women primarily in high-income nations such as UK, Switzerland and Norway coupled represents significant risk factors for COPD. Moreover, the increasing exposure of women in lower-income countries such as India, China and Brazil to indoor air pollution resulting from the combustion of solid fuel for heating and cooking purpose should further trigger the erdosteine market revenue.
 

Pharmaceutical end-use surpassed USD 45 million in 2020 and is projected to reach USD 80 million up to 2027. Increasing technological advancement, increase in the geriatric population and growing research & development spending by pharmaceutical companies should augment market share. Increasing consumer preference for preventive healthcare especially with the advent of the COVID-19 pandemic which boosted the demand for respiratory drugs should accelerate the erdosteine market growth.
 

Significant economic growth in emerging nations such as China, Brazil and India resulted in increased expenditure on healthcare and favorable government policies boosted foreign direct investment (FDI) which should trigger erdosteiene market growth. Moreover, the high prevalence of respiratory diseases such as asthma and lung disease primarily in Germany, UK and France have overburdened the healthcare systems and should drive product demand in pharmaceutical sector.
 

North America should grow at a CAGR of over 8% to surpass USD 80 million by 2027 pertaining to the substantial prevalence of cigarette and tobacco smoking. The region has witnessed a growing adoption of e-cigarettes on account of increasing anti-smoking campaigns, rising cigarette prices and rising consumer preference for alternatives to combustible cigarettes. The high incidence of smoking has led to a rise in COPD cases, owing to weakening of lungs.
 

North America has witnessed a significant increase in mental health disorders such as anxiety, restlessness and suicidal thoughts primarily in young adults which is associated with a rise in smoking, drugs and alcohol consumption. The low perceived harm of e-cigarettes, desirable flavours, and rising curiosity among youth should drive e-cigarette adoption in the region which is likely to boost COPD prevalence and stimulate the erdosteine market share.
 

Erdosteine Market Share

Global erdosteine industry share is consolidated, and the key players include:

• Reipharm AB
• Hanmi Pharmaceutical
• Hikma Pharmaceuticals
• Shandong Luoxin Pharmaceutical
• Zhejiang Kangle Pharmaceutical Co., Ltd

Various manufacturers are primarily focusing on strategic initiatives such as acquisitions, partnerships and joint ventures to expand product portfolio and achieve market growth. Leading companies are also engaged in significant research & development activities to expand the application potential of their products and gain additional customers.
 

For instance, Recipharm, a leading pharmaceutical company announced in 2020 that it was conducting research on its erdosteine product to investigate if it improved the recovery rate of COVID-19 patients after discharge from hospital. Various clinical studies were conducted to verify if the product enhances respiratory symptoms and reduces the time required to achieve a negative COVID-19 test result.
 

The global erdosteine market report includes in-depth coverage of the industry with estimates & forecast in terms of volume in Tons & revenue in USD Million from 2016 to 2027 for the following segments:

Click here to Buy Section of this Report

By Application

• Bronchitis
• COPD
• Nasopharyngitis
• Others

By End-Use

• Pharmaceutical
• CMOs
• Research Institutes

The above information has been provided for the following countries:

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE